NEW EUROPEAN GUIDELINES ON PHARMACOTHERAPY OF CHRONIC HEART FAILURE AND EVIDENCE-BASED DATA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is devoted to clinical recommendations of the European Society of Cardiology and the Heart Failure Association on diagnosis and treatment of acute and chronic heart failure 2016. The attention is focused on the pharmacotherapy of heart failure with reduced left ventricular ejection fraction. The data of a number of meta-analyses, randomized clinical trials and indications for use of the new drug, sacubitril/ valsartan combining neprilysin inhibitor (neutral endopeptidase) and angiotensin II receptor (type I) blocker are discussed in detail.

Full Text

Restricted Access

About the authors

V. N Larina

FSBEI HE “Russian National Scientific Medical University n.a. N.I. Pirogov" of RMH

Moscow

M. V Leonova

FSBEI HE “Russian National Scientific Medical University n.a. N.I. Pirogov" of RMH

Email: anti23@mail.ru
MD, Prof., Head of the Department of Clinical Pharmacology of the Medical Faculty Moscow

I. I Chukaeva

FSBEI HE “Russian National Scientific Medical University n.a. N.I. Pirogov" of RMH

Moscow

References

  1. Ponikowski P., Voors A., Anker S., Bueno H., Cleland J., Coats A., Falk V., Gonzalez-Juanatey J., Harjola V., Jankowska E., Jessup M., Linde S., Nihoyannopoulos P., Parissis J., Pieske B., Riley J., Rosano G., Ruilope L., Ruschitzka F., Rutten F., van der Meer P 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart. J. 2016.
  2. Maggioni A., Anker S., Dahlstrom U., Filippatos G., Ponikowski P., Zannad F., Amir O., Chioncel O., Leiro M., Drozdz J., Erglis A., Fazlibegovic E., Fonseca C., Fruhwald F., Gatzov P., Goncalvesova E., Hassanein M., Hradec J., Kavoliuniene A., Lainscak M., Logeart D., Merkely B., Metra M., Persson H., Seferovic P., Temizhan A., Tousoulis D., Tavazzi L. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur. J. Heart. Fail. 2013;15:1173-84.
  3. Packer M., Coats A., Fowler M., Katus H., Krum H., Mohacsi P., Rouleau J., Tendera M., Castaigne A., Roecker E., Schultz M., DeMets D. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001;344:1651-58.
  4. Flather M., Shibata M., Coats A., Van Veldhuisen D., Parkhomenko A., Borbola J., Cohen-Solal A., Dumitrascu D., Ferrari R., Lechat P., Soler-Soler J., Tavazzi L., Spinarova L., Toman J., Bohm M., Anker S., Thompson S., Poole-Wilson P., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart. J. 2005;26:215-25.
  5. Kotecha D., Holmes J., Krum H., Altman D., Manzano L., Cleland J., Lip G., Coats A., Andersson B., Kirchhof P., von Lueder T., Wedel H., Rosano G., Shibata M., Rigby A., Flather M. Efficacy of ß-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-43.
  6. Pitt B, Zannad F., Remme W., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999;341:709-17.
  7. Zannad F., McMurray J., Krum H., Van Veldhui-sen D., Swedberg K., Shi H., Vincent J., Pocock S., Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011;364:11-21.
  8. Collier T., Pocock S., McMurray J., Zannad F., Krum H., Veldhuisen D., Swedberg K., Shi H., Vincent J., Pitt B. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur. Heart. J. 2013;34:2823-29.
  9. Danjuma M.I., Mukherjee I., Makaronidis J., Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr. Hypertens. Rep. 2014;16:414.
  10. Mangiafico S., Costello-Boerrigter L.C., Andersen I., Cataliotti A., Burnett J. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart. J. 2012.
  11. Леонова М.В. Новые и перспективные лекарственные препараты, блокирующие ренин-ангиотензин-альдостероновую систему. РМЖ. 2013;21(17):886-90.
  12. McMurray J., Packer M., Desai A., Gong J., Lefkowitz M., Rizkala A., Rouleau J., Shi V., Solomon S., Swedberg K., Zile M. for the PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N. Engl. J. Med. 2014;371:993-1004.
  13. Granger C., McMurray J., Yusuf S., Held P., Michelson E., Olofsson B., Ostergren J., Pfeffer M., Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-76.
  14. Cohn J., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001;345: 1667-75.
  15. Swedberg K., Komajda M., Bohm M., Borer J., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT) a randomised placebo-controlled study. Lancet. 2010;376:875-85.
  16. Cohn J., Archibald D., Ziesche S., Franciosa J., Harston W., Tristani F., Dunkman W., Jacobs W., Francis G., Flohr K., Goldman S., Cobb F., Shah P., Saunders R., Fletcher R., Loeb H., Hughes V., Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N. Engl. J. Med. 1986;314:1547-52.
  17. Vamos M., Erath J., Hohnloser S. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur. Heart. J. 2015;36(28):183-88.
  18. Chen Y., Cai X., Huang W., Wu Y., Huang Y., Hu Y. Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis. Medicine (Baltimore). 2015;94(52):e2409.
  19. Qureshi W., O'Neal W.T., Soliman E.Z., Al-Mallah M.H. Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiol. J. 2016;23(3):333-43.
  20. Wang Z., Zhang R., Chen M., Wang Q., Zhang Y., Huang X., Wang J., Yan J., Li Y. Digoxin Is Associated With Increased All-cause Mortality in Patients With Atrial Fibrillation Regardless of Concomitant Heart Failure: A Meta-analysis. J. Cardiovasc. Pharmacol. 2015;66(3):270-75.
  21. Shah M., Tsadok A., Jackevicius C., Essebag V., Behlouli H., Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients X65 years of age with versus without heart failure. Am. J. Cardiol. 2014;114(3):401-6.
  22. Chamaria S., Desai A., Reddy P., Olshansky B., Dominic P. Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. Cardiol. Res. Pract. 2015;2015: 314041.
  23. Ziff O., Lane D., Samra M., Griffith M., Kirchhof P., Lip G., Steeds R., Townend J., Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351: h4451.
  24. Tavazzi L., Maggioni A., Marchioli R., Barlera S., Franzosi M., Latini R., Lucci D., Nicolosi G., Porcu M., Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372: 1223-30.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies